Literature DB >> 25169849

TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future.

Lisa M Sedger1, Michael F McDermott2.   

Abstract

Tumor Necrosis Factor (TNF), initially known for its tumor cytotoxicity, is a potent mediator of inflammation, as well as many normal physiological functions in homeostasis and health, and anti-microbial immunity. It also appears to have a central role in neurobiology, although this area of TNF biology is only recently emerging. Here, we review the basic biology of TNF and its normal effector functions, and discuss the advantages and disadvantages of therapeutic neutralization of TNF - now a commonplace practice in the treatment of a wide range of human inflammatory diseases. With over ten years of experience, and an emerging range of anti-TNF biologics now available, we also review their modes of action, which appear to be far more complex than had originally been anticipated. Finally, we highlight the current challenges for therapeutic intervention of TNF: (i) to discover and produce orally delivered small molecule TNF-inhibitors, (ii) to specifically target selected TNF producing cells or individual (diseased) tissue targets, and (iii) to pre-identify anti-TNF treatment responders. Although the future looks bright, the therapeutic modulation of TNF now moves into the era of personalized medicine with society's challenging expectations of durable treatment success and of achieving long-term disease remission.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Inflammation; Monoclonal antibody; Neuropathology; Tumor necrosis factor; Tumor necrosis factor receptor

Mesh:

Substances:

Year:  2014        PMID: 25169849     DOI: 10.1016/j.cytogfr.2014.07.016

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  246 in total

1.  Assessment of the involvement of the macrophage migration inhibitory factor-glucocorticoid regulatory dyad in the expression of matrix metalloproteinase-2 during periodontitis.

Authors:  Josefine Hirschfeld; Mohammed Howait; Alexandru Movila; Marijo Parčina; Isabelle Bekeredjian-Ding; James Deschner; Søren Jepsen; Toshihisa Kawai
Journal:  Eur J Oral Sci       Date:  2017-08-04       Impact factor: 2.612

Review 2.  Hepatotoxicity Associated with the Use of Anti-TNF-α Agents.

Authors:  Joshua B French; Maurizio Bonacini; Marwan Ghabril; David Foureau; Herbert L Bonkovsky
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

Review 3.  Tissue-Intrinsic Tumor Hotspots: Terroir for Tumorigenesis.

Authors:  Yoichiro Tamori; Wu-Min Deng
Journal:  Trends Cancer       Date:  2017-04-04

4.  Noncompetitive inhibitors of TNFR1 probe conformational activation states.

Authors:  Chih Hung Lo; Tory M Schaaf; Benjamin D Grant; Colin Kin-Wye Lim; Prachi Bawaskar; Courtney C Aldrich; David D Thomas; Jonathan N Sachs
Journal:  Sci Signal       Date:  2019-07-30       Impact factor: 8.192

Review 5.  Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?

Authors:  Alain Menzel; Hanen Samouda; Francois Dohet; Suva Loap; Mohammed S Ellulu; Torsten Bohn
Journal:  Antioxidants (Basel)       Date:  2021-03-09

6.  Minor structural modifications of bisphenol A strongly affect physiological responses of HepG2 cells.

Authors:  F Padberg; P Tarnow; A Luch; S Zellmer
Journal:  Arch Toxicol       Date:  2019-05-04       Impact factor: 5.153

Review 7.  The role of lymphotoxin-α in rheumatoid arthritis.

Authors:  Tomohiro Hirose; Yuri Fukuma; Ayumu Takeshita; Keiichiro Nishida
Journal:  Inflamm Res       Date:  2018-03-14       Impact factor: 4.575

Review 8.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

9.  A Stochastic Petri Net-Based Model of the Involvement of Interleukin 18 in Atherosclerosis.

Authors:  Dorota Formanowicz; Agnieszka Rybarczyk; Marcin Radom; Krzysztof Tanaś; Piotr Formanowicz
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

10.  X-linked ectodermal dysplasia receptor (XEDAR) gene silencing prevents caspase-3-mediated apoptosis in Sjögren's syndrome.

Authors:  Margherita Sisto; Loredana Lorusso; Sabrina Lisi
Journal:  Clin Exp Med       Date:  2015-12-11       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.